Financial Data and Key Metrics Changes - Revenue for Q1 2025 reached $9.6 million, an 18% increase year-over-year, marking a record for the company [7][23] - Gross margin improved to 62.8%, a 50 basis point increase compared to the same period last year [9][26] - The company raised its 2025 revenue guidance to a range of $38.5 million to $39.5 million, representing a 15% to 17% year-over-year growth [9][29] Business Line Data and Key Metrics Changes - Domestic core revenues were $6.9 million, a 16% increase year-over-year, driven by new patient starts and market share gains [23] - International core business revenues reached $2.4 million, representing a 36% growth over the prior year, driven by expansion into new geographies and a key tender win [24][12] - Pharma services and clinical trials revenues declined by 39% to $300,000 due to lower clinical trial orders [24] Market Data and Key Metrics Changes - The overall SCIG market grew approximately 10% in Q1, while the company's domestic core business grew 16% [12] - Internationally, the company achieved 36% growth, driven by patient growth and new distributor relationships in the Middle East and North Africa [12] - The total international SCIG total addressable market (TAM) is estimated at $60 million, with the company currently holding approximately a 10% share [16] Company Strategy and Development Direction - The company aims to expand its platform to support subcutaneous delivery of additional large volume drugs, capitalizing on the shift from IV to subcutaneous formulations [11] - The strategic vision includes strengthening the core business while pursuing new drug opportunities, with a focus on operational efficiencies and market expansion [10][11] - The company plans to submit two additional commercialized drugs for FDA clearance by the end of 2025, bringing the total pipeline to five planned submissions [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for the core business, citing a resilient market growth even amid macroeconomic uncertainties [15] - The company is optimistic about its international expansion plans, targeting a growth in market share from 10% to 30%-40% over the next several years [16] - Management reiterated expectations for positive cash flow from operations in 2025, with a focus on improving operating leverage [30] Other Important Information - The company has nine active collaborations with pharmaceutical partners, with a robust pipeline of 17 total opportunities [17] - The company is actively monitoring the changing policy environment regarding tariffs and supply chain impacts [27] Q&A Session Summary Question: Thoughts on adding new drugs without current partnerships - Management is excited about pursuing drugs independently, driven by strong relationships with specialty pharmacies and the potential for revenue growth with minimal investment [41][43] Question: Revenue cadence throughout the year - Management expects international revenue growth to be around 30%, with some impact from distributor stocking orders in Q2 [46][48] Question: Prefilled syringe opportunity and tender details - Prefilled syringe penetration in the US is now over 65%, with plans for further penetration outside the US [50][51] Question: Update on ePump opportunity and distributor dynamics - The company sees potential for increased volumes of consumables with e pumps, driven by new market openings and share gains [60] Question: Market opportunity for new drugs - The iron chelation drug has an estimated patient base of 30,000, while the antibiotic drug has over 300,000 patients, with significant potential for home administration [88][90]

Financial Performance & Guidance - KORU Medical achieved Q1 2025 revenues of $9.6 million, representing an 18% increase year-over-year[8] - The company's core business experienced 21% growth, driven by recurring revenues, new patient starts, share expansion, and geographic expansion[8] - Gross margin improved to 62.8%, a 50 basis points increase[7] - KORU Medical raised its 2025 revenue guidance to $38.5-$39.5 million, projecting 15%-17% growth, and reaffirmed 61%-63% gross margins, with positive cash flow from operations expected for the full year[7] Strategic Growth & Market Expansion - Domestic core business revenue grew by 16% year-over-year[12] - International core business experienced 36% year-over-year growth[12] - Approximately 75% of KORU's revenue is recurring, excluding initial pump sales and Novel Therapies service revenue[15] Pipeline & Future Catalysts - KORU Medical plans to submit for FDA 510(k) clearance with 2 commercialized drugs on the Freedom Infusion System in 2025[8] - The company has 15 pharma collaborations in total, with 2 added year-to-date in 2025[13] - KORU Medical estimates its international market share at 10% with a goal of 30-40%[19]

Revenue and Profitability - The company reported net revenues of $9.6 million for Q1 2025, a 17.5% increase from $8.2 million in Q1 2024, driven by a 16.4% growth in domestic core revenues and a 35.6% increase in international core revenues [75]. - Gross profit for Q1 2025 was $6.0 million, an 18.5% increase from $5.1 million in Q1 2024, with a gross margin of 62.8%, up from 62.3% in the prior year [76][81]. - The company experienced a net loss of $1.2 million in Q1 2025, a 39.8% improvement from a net loss of $1.9 million in Q1 2024 [85]. Expenses - Operating expenses increased to $7.3 million in Q1 2025, compared to $7.1 million in Q1 2024, primarily due to a rise in selling, general, and administrative expenses [77][83]. - Selling, general, and administrative expenses rose by 11.2% to $6.0 million in Q1 2025, driven by increased compensation-related expenses and legal fees [83]. - Research and development expenses decreased by 24.5% to $1.1 million in Q1 2025, primarily due to timing of project spending [84]. Cash Flow and Investments - Cash on hand as of March 31, 2025, was $8.7 million, with inventory increasing to $3.3 million, reflecting a $0.5 million rise from December 31, 2024 [86][87]. - Net cash used in operating activities was $0.2 million for Q1 2025, an improvement from $0.3 million in Q1 2024, primarily due to a lower net loss and changes in working capital [90][91]. - The company invested $0.4 million in capital expenditures for manufacturing equipment related to new consumables production lines in Q1 2025 [92]. - The company anticipates that cash on hand and cash flows from operations will be sufficient to meet requirements for at least the next twelve months [88]. Accounting and Market Risk - No significant accounting policies have been adopted that would impact the financial statements [94]. - There are no applicable quantitative and qualitative disclosures about market risk [95].

[Q1 2025 Financial & Operational Highlights](index=1&type=section&id=Q1%202025%20Financial%20%26%20Operational%20Highlights) KORU Medical achieved record Q1 2025 net revenues of **$9.6 million**, an 18% year-over-year increase, driven by 21% core business growth and new patient starts, leading to raised full-year guidance and planned 510(k) submissions [Overview](index=1&type=section&id=Recent%20Highlights) KORU Medical achieved record Q1 2025 net revenues of **$9.6 million**, an 18% year-over-year increase, driven by 21% core business growth and new patient starts, leading to raised full-year guidance and planned 510(k) submissions Q1 2025 Key Performance Indicators | Metric | Q1 2025 ($) | Change vs. Q1 2024 | | :--- | :--- | :--- | | **Net Revenues** | $9.6 million | +18% | | **Core Business Net Revenues** | $9.4 million | +21% | | **Gross Profit** | $6.0 million | +19% | | **Gross Margin** | 62.8% | +50 bps | | **Ending Cash Balance** | $8.7 million | - | | **Quarterly Cash Usage** | $0.8 million | - | - The CEO attributed the strong performance to over **20% growth** in the core business, driven by new patient starts and market share gains in both domestic and international markets[3](index=3&type=chunk) - The company announced plans to submit for FDA 510(k) clearance for two commercialized drugs with the Freedom Infusion System™ in 2025[6](index=6&type=chunk) [Q1 2025 Financial Performance Analysis](index=1&type=section&id=Q1%202025%20Financial%20Performance%20Analysis) This section analyzes the company's Q1 2025 financial results, detailing revenue drivers, profitability improvements, and cash flow position [Net Revenues](index=1&type=section&id=Net%20Revenues) Total net revenues for Q1 2025 increased **17.5% to $9.6 million**, driven by **20.8% growth in the Total Core business** to $9.4 million, despite a decrease in Pharma Services and Clinical Trials revenue Net Revenues Breakdown (Three Months Ended March 31) | Revenue Segment | 2025 ($) | 2024 ($) | Change (%) | | :--- | :--- | :--- | :--- | | Domestic Core | $6,927,964 | $5,953,865 | +16.4% | | International Core | $2,428,662 | $1,790,483 | +35.6% | | **Total Core** | **$9,356,626** | **$7,744,348** | **+20.8%** | | Pharma Services and Clinical Trials | $278,449 | $453,450 | -38.6% | | **Total Net Revenues** | **$9,635,075** | **$8,197,798** | **+17.5%** | - Domestic core revenue growth was driven by higher pump and consumable volumes from new patient starts and market share gains[4](index=4&type=chunk) - International core revenue growth was primarily due to higher volumes from geographical expansion and a tender win with an Ig pharma partner, including approximately **$0.4 million of distributor stocking**[4](index=4&type=chunk) [Profitability Analysis](index=1&type=section&id=Profitability%20Analysis) Gross profit increased **18.5% to $6.0 million** with gross margin expanding **50 basis points to 62.8%**, leading to a significant reduction in net loss to **$(1.2) million** or **$(0.03) per share** Profitability Metrics (Three Months Ended March 31) | Metric | 2025 ($) | 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | **Gross Profit** | $6.0 million | $5.1 million | +$0.9M | | **Gross Margin** | 62.8% | 62.3% | +50 bps | | **Total Operating Expenses** | $7.3 million | $7.1 million | +$0.2M | | **Net Loss** | $(1.2) million | $(1.9) million | +$0.7M | | **Net Loss Per Share** | $(0.03) | $(0.04) | +$0.01 | - The increase in gross margin was primarily driven by favorable changes in product revenue mix[5](index=5&type=chunk) - Operating expenses increased due to higher compensation for temporary staff and legal fees, partially offset by lower severance and R&D expenses[7](index=7&type=chunk) [Cash Flow and Financial Position](index=2&type=section&id=Cash%20Flow%20and%20Financial%20Position) The company concluded Q1 2025 with **$8.7 million in cash**, reflecting **$0.8 million in cash usage**, while Adjusted EBITDA significantly improved to a loss of **$(0.2) million** - Cash and cash equivalents were **$8.7 million** as of March 31, 2025, with a cash usage of **$0.8 million** in Q1[10](index=10&type=chunk) Adjusted EBITDA (Three Months Ended March 31) | Metric | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | **Adjusted EBITDA** | ($0.2) million | ($0.9) million | | **Adjusted Diluted EPS** | $0.00 | ($0.02) | [Full Year 2025 Guidance](index=1&type=section&id=2025%20Guidance) This section outlines KORU Medical's updated financial projections for the full year 2025, including revenue, gross margin, and cash flow from operations [Updated Guidance](index=1&type=section&id=Updated%20Guidance) KORU Medical raised its full-year 2025 revenue guidance to **$38.5 million to $39.5 million** and reiterated gross margin guidance of **61% to 63%**, expecting positive cash flow from operations Full Year 2025 Guidance | Metric | Updated Guidance ($) | Prior Guidance ($) | | :--- | :--- | :--- | | **Net Revenues** | $38.5 - $39.5 million | $38.0 - $39.0 million | | **Gross Margin** | 61% - 63% (Reiterated) | 61% - 63% | | **Cash Flow from Operations** | Positive (Reiterated) | Positive | [Financial Statements](index=3&type=section&id=Financial%20Statements) This section presents the detailed financial statements, including balance sheets, statements of operations, and statements of cash flows for the reported periods [Balance Sheets](index=3&type=section&id=KORU%20MEDICAL%20SYSTEMS%2C%20INC.%20BALANCE%20SHEETS) As of March 31, 2025, total assets remained stable at **$27.2 million**, while total liabilities increased to **$10.9 million** and total stockholders' equity decreased to **$16.3 million** Selected Balance Sheet Items | Account | March 31, 2025 ($) | December 31, 2024 ($) | | :--- | :--- | :--- | | **Cash and cash equivalents** | $8,735,834 | $9,580,947 | | **Total Current Assets** | $18,999,028 | $19,132,410 | | **Total Assets** | $27,216,167 | $27,218,515 | | **Total Current Liabilities** | $7,799,277 | $7,201,820 | | **Total Liabilities** | $10,871,136 | $10,404,836 | | **Total Stockholders' Equity** | $16,345,031 | $16,813,679 | [Statements of Operations](index=4&type=section&id=KORU%20MEDICAL%20SYSTEMS%2C%20INC.%20STATEMENTS%20OF%20OPERATIONS) For Q1 2025, the company reported a net loss of **$(1.2) million** or **$(0.03) per share**, a significant improvement from the **$(1.9) million** loss in Q1 2024, driven by higher revenues and gross profit Statement of Operations Summary (Three Months Ended March 31) | Account | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | **Net Revenues** | $9,635,075 | $8,197,798 | | **Gross Profit** | $6,046,335 | $5,103,298 | | **Total Operating Expenses** | $7,291,340 | $7,064,664 | | **Net Operating Loss** | $(1,245,005) | $(1,961,366) | | **Net Loss** | $(1,166,237) | $(1,935,958) | | **Net Loss Per Share** | $(0.03) | $(0.04) | [Statements of Cash Flows](index=4&type=section&id=KORU%20MEDICAL%20SYSTEMS%2C%20INC.%20STATEMENTS%20OF%20CASH%20FLOWS) Net cash used in operating activities improved to **$(0.2) million** for Q1 2025, with total net decrease in cash of **$(0.8) million** for the quarter Cash Flow Summary (Three Months Ended March 31) | Activity | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | **Net Cash Used in Operating Activities** | $(237,467) | $(346,720) | | **Net Cash Used in Investing Activities** | $(446,838) | $(133,083) | | **Net Cash Used in Financing Activities** | $(160,808) | $(182,120) | | **Net Decrease in Cash** | $(845,113) | $(661,923) | | **Cash at End of Period** | $8,735,834 | $10,820,317 | [Supplemental Information](index=5&type=section&id=Supplemental%20Information) This section provides additional financial details, including reconciliations of GAAP to non-GAAP financial measures for a clearer understanding of underlying performance [Reconciliation of GAAP to Non-GAAP Measures](index=5&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) This section reconciles GAAP net loss to non-GAAP Adjusted EBITDA, which improved to **$(0.2) million** in Q1 2025, and GAAP diluted EPS to non-GAAP adjusted diluted EPS, with key adjustments for stock-based compensation and litigation expenses Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA | Line Item | Q1 2025 ($) | Q1 2024 ($) | | :--- | :--- | :--- | | **GAAP Net Loss** | **$(1,166,237)** | **$(1,935,958)** | | Stock-based Compensation | $697,590 | $699,718 | | Depreciation and Amortization | $217,357 | $231,369 | | Litigation Expense | $133,411 | $— | | Interest (Income), Net | $(73,180) | $(37,187) | | **Adjusted EBITDA** | **$(191,059)** | **$(942,729)** | - Non-GAAP calculations exclude the effects of reorganization charges, stock-based compensation expense, and litigation expenses related to a patent infringement claim[28](index=28&type=chunk)[29](index=29&type=chunk)[30](index=30&type=chunk)

Financial Data and Key Metrics Changes - Q4 revenues grew by 23% year-over-year, totaling $8.8 million, while full-year revenues reached $33.6 million, representing an 18% increase [13][37] - Gross margins for Q4 were 62.9%, a 260 basis point improvement from the previous year, and full-year gross margins were 63.4%, reflecting a 480 basis point improvement [39][40] - The year-end cash balance was $9.6 million, exceeding expectations, with positive cash flow generated in Q4 [15][41] Business Line Data and Key Metrics Changes - Domestic core revenues increased by 20% in Q4 and 12% for the full year, driven by strong pump and consumable volume growth [35][38] - International core revenues grew by 14% in Q4 and 32% for the full year, supported by market penetration and geographic expansion [36][38] - Novel therapies revenues reached $700,000 in Q4, marking a 122% increase, and full-year revenues were $2.4 million, a 62% growth [37][39] Market Data and Key Metrics Changes - The U.S. SCIg market grew approximately 10% in 2024, marking the eighth consecutive quarter of year-over-year growth [17] - The international SCIg market also showed strong growth, with KORU entering new geographies in the Middle East, North Africa, and Eastern Europe [20][21] - The overall large-volume subcutaneous market is rapidly expanding, with over 18 large-volume drugs in development [11] Company Strategy and Development Direction - KORU Medical aims to become a global leader in large-volume subcutaneous drug delivery, focusing on expanding its market share in both domestic and international markets [9][12] - The company is transitioning its Novel Therapies segment to Pharma Services and Clinical Trials to better reflect its business model [24][46] - KORU plans to launch three new products in 2025, enhancing patient comfort and convenience [53][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining mid-teen growth rates in recurring revenue, driven by increased market share and new product launches [27][28] - The company anticipates operational cash flow positivity for the full year of 2025, with revenue guidance set between $38 million and $39 million [16][50] - Management noted potential supply disruptions from FDA announcements are expected to be short-term and manageable [25] Other Important Information - The company has approximately 49,000 patients, with 75% of revenues coming from recurring sources, indicating a strong recurring revenue base [26] - KORU holds about 10% share of a $60 million o-US SCIg market, indicating significant growth potential [28] Q&A Session Summary Question: Can you break down the 2025 guidance for domestic and international growth? - Management expects domestic revenue growth between 10% and 15% and international growth over 20%, with novel therapies contributing $2 million to $3 million [62] Question: What drives the above-market growth in 2025? - Growth will be driven by new geographies, increased market share, and new customer acquisitions, particularly in the international space [64][66] Question: What is the status of the oncology opportunity? - The company is focused on market assessment, reimbursement strategies, and establishing distribution partnerships for the oncology product [70] Question: Can you elaborate on the e-pump opportunity? - The e-pump market is seen as a significant growth driver, with KORU currently holding over 10% market share and plans for further penetration [82] Question: How do you view gross margin expansion with the new product portfolio? - The new consumables launch is expected to drive efficiencies and potentially increase gross margins to over 65% in the long term [85]

KORU Medical Systems (KRMD) Q4 2024 Earnings Call March 12, 2025 04:30 PM ET Company Participants Louisa Smith - PrincipalLinda Tharby - President and CEOTom Adams - Chief Financial OfficerMichaela Smith - Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareFrank Takkinen - Senior Research AnalystJason Bednar - Senior Research AnalystAnderson Schock - Research Analyst Operator Greetings, and welcome to the Coram Medical Systems Fourth Quarter and Ful ...

Market Position and Strategy - KORU Medical focuses on developing innovative large volume subcutaneous infusion solutions, primarily targeting the subcutaneous drug delivery market regulated by the FDA[23]. - The company generates revenue from three sources: domestic core (US and Canada), international core, and novel therapies, with a focus on immunoglobulin delivery for PIDD and CIDP[24]. - KORU Medical aims to strengthen its position in the subcutaneous immunoglobulin (SCIg) market and expand into emerging subcutaneous drug therapies, leveraging the FREEDOM Infusion System[27]. - The company identifies key market trends driving SCIg growth, including increasing diagnoses of PIDD and expansion of on-label SCIg indications[29]. - KORU Medical estimates that at least 100 large-volume drugs greater than 2ml are in clinical development utilizing subcutaneous infusion, with approximately 20% being greater than 10ml[32]. - The FREEDOM System remains the market-leading delivery system in the U.S. for SCIg treatments, with increasing patient access expected as new drugs are developed[36]. - The company’s strategy includes ongoing clinical and product innovation, strategic partnerships, and commercial excellence to enhance its global market position[31]. Product Development and Innovation - The FREEDOM System is FDA 510(k) cleared and certified for several on-label subcutaneous indications, including Cutaquig®, Cuvitru®, and Hizentra®[35]. - HIgH-Flo Subcutaneous Safety Needle Sets are integral to the FREEDOM System, available in 26- and 24-gauge sizes for subcutaneous self-administration[37]. - The company invested $5.3 million and $5.7 million in research and development for the years ended December 31, 2024 and 2023, respectively, with plans for further investments in a next-generation infusion pump[43]. - The company is committed to innovation and product development, recognizing its importance for long-term success[43]. - The company’s strategy includes investing in innovation and new product development to achieve revenue growth, which requires substantial resources[73]. Regulatory and Compliance Challenges - The company faces regulatory scrutiny from the FDA and other authorities, which impacts the development, testing, and marketing of its medical devices[44]. - The company’s products are subject to ongoing regulatory compliance even after receiving FDA clearance, which can impact marketing and sales strategies[52]. - The company aims to comply with EU MDR regulations by December 2028, which will require significant investment to avoid losing the ability to sell products in the EU[75][76]. - The company is subject to extensive regulatory requirements, including compliance with the new EU Medical Device Regulation (MDR) effective May 2021, which will require significant investment to implement[116]. - Compliance with complex regulations, particularly from the FDA, is critical, and failure to maintain approvals could adversely affect financial condition and operations[90]. Financial Performance and Risks - The company does not currently intend to pay dividends on its common stock, which may affect investor attractiveness[28]. - The FREEDOM System's sales are primarily through six distributors, accounting for approximately 75% of net revenues, with one U.S. distributor contributing about 35%[40]. - The company faces significant risks related to patent litigation, which could result in loss of patent protection and substantial sales losses[107]. - The company may need additional funding in the future to support product development and commercialization efforts, which could lead to shareholder dilution if raised through equity offerings[137]. - The company’s financial results may be adversely affected by significant price increases from single-source suppliers[127]. Competition and Market Dynamics - Competition for the FREEDOM System includes various types of pumps, with key factors influencing selection being safety, cost-effectiveness, and ease of use[60]. - The company faces competition from a wide range of international and domestic companies in the infusion market, which may have greater financial and marketing resources[84]. - The company faces competition from generic and biosimilar therapies, which could significantly reduce the commercial viability of brand name injectable therapies[125]. - The medical technology industry is experiencing significant consolidation, leading to increased competition and downward pricing pressure for medical device suppliers[87]. Operational and Supply Chain Considerations - The company manufactures 100% of its pump product volume and 15% of consumables at its Mahwah, NJ facility, while 85% of consumables are sourced from Command Medical Products in Nicaragua[41]. - The company does not have binding contracts with suppliers, relying on single-source suppliers for components, which may pose risks to meeting customer demand[42]. - The company has a five-year agreement with Command established in 2020, but lacks long-term agreements with other suppliers, complicating supply chain stability[130]. - The company sources most components and raw materials from single suppliers, which poses risks to timely delivery and cost-effectiveness[126]. Human Resources and Management - As of December 31, 2024, the company employed 80 full-time employees, with approximately 49% being female and 43% being minorities[62]. - The company has a dedicated internet-based learning platform for employee training, aligning with their responsibilities and career development[63]. - The company maintains competitive compensation and benefits to attract and retain skilled labor, including health insurance and a 401(k) plan with matching contributions[64]. - The company does not maintain "key man" insurance policies, making it vulnerable to the loss of key management personnel[111]. - The company has made several changes to its management structure, which may lead to integration challenges and affect business operations[139]. External Economic Factors - The company is exposed to foreign currency exchange risks, which could affect revenues derived from international sales[144]. - The company faces risks from potential tariffs, including a 25% tariff on imports from Canada and Mexico and a 10% tariff on imports from China, which could adversely affect its financial results[142]. - Changes in tax or labor laws could increase operational costs and reduce profit margins, impacting overall financial performance[140]. - Rising inflation rates have increased economic uncertainty, potentially requiring the company to raise prices to maintain operating margins[154]. - The company faces uncertainties in the UK market due to Brexit, which may impact business operations and regulatory compliance[155]. Legal and Liability Risks - Product liability claims and lawsuits could result in significant legal costs and negatively affect the company's reputation and financial condition[104]. - Quality management is essential for maintaining customer confidence; quality issues could lead to recalls and regulatory actions, adversely impacting business[100]. - Protection of patents and proprietary rights is crucial; loss of intellectual property rights could materially damage competitiveness and business prospects[105]. Environmental and Social Considerations - Increased focus on environmental, social, and governance (ESG) issues may adversely affect the company's reputation and financial condition if not addressed appropriately[157]. - Climate change poses immediate and long-term risks, including increased operational costs and supply chain disruptions[158].

Company Overview - KORU Medical Systems Inc. (KRMD) currently holds a Momentum Style Score of A, indicating strong momentum potential [3] - The company has a Zacks Rank of 2 (Buy), suggesting favorable investment conditions [4] Price Performance - KRMD shares have increased by 3.28% over the past week, outperforming the Zacks Medical - Instruments industry, which rose by 1.15% [6] - Over the past month, KRMD's price change is 2.76%, while the industry average is 3.26% [6] - In the last quarter, KRMD shares rose by 40.41%, and over the past year, they have increased by 93.4%, significantly outperforming the S&P 500, which moved 5.86% and 27.32% respectively [7] Trading Volume - KRMD's average 20-day trading volume is 106,547 shares, which serves as a useful price-to-volume baseline [8] Earnings Outlook - In the past two months, one earnings estimate for KRMD has moved higher, while none have moved lower, resulting in a consensus estimate increase from -$0.14 to -$0.13 [10] - For the next fiscal year, two estimates have been revised upwards with no downward revisions [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, KRMD is positioned as a promising investment opportunity [12]

Financial Results - KORU Medical Systems, Inc. announced preliminary financial results for the fiscal quarter and year ended December 31, 2024[4]. - The financial results are based on current estimates and are subject to change pending completion of closing and review procedures[5]. - The company has not provided specific financial figures in the current report but will disclose them in future filings[5]. Investor Relations - An investor presentation was posted on January 13, 2025, which may be used for presentations to investors and analysts[7]. - The press release and investor presentation are available on the company's investor relations website[7]. - The company has not committed to publicly updating or revising the information provided in the report[7]. Company Classification and Trading - The company is classified as an emerging growth company under the Securities Act of 1933[4]. - The company is headquartered in Mahwah, NJ, and its common stock is traded on The Nasdaq Stock Market under the symbol KRMD[4]. Report Details - The report does not include any liabilities under Section 18 of the Exchange Act[6]. - The report was signed by Linda Tharby, President and CEO, on January 13, 2025[11].

Financial Performance - KORU Medical Systems Inc. reported a quarterly loss of $0.03 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company posted revenues of $8.18 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 6.86%, and up from $7 million in the same quarter last year [2] - Over the last four quarters, KORU Medical has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Stock Performance - KORU Medical shares have increased by approximately 21% since the beginning of the year, while the S&P 500 has gained 25.5% [3] - The current Zacks Rank for KORU Medical is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $8.01 million, and for the current fiscal year, it is -$0.13 on revenues of $32.28 million [7] - The estimate revisions trend for KORU Medical is mixed, and future earnings expectations will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Instruments industry, to which KORU Medical belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]